Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7Z3A

AMC009 SOSIPv5.2 in complex with Fabs ACS101 and ACS124

これはPDB形式変換不可エントリーです。
7Z3A の概要
エントリーDOI10.2210/pdb7z3a/pdb
EMDBエントリー14474
分子名称AMC009 SOSIPv5.2 envelope glycoprotein gp120, beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (11 entities in total)
機能のキーワードhiv-1, antibodies, cd4-binding site, gp41-gp120 interface, viral protein
由来する生物種Human immunodeficiency virus 1
詳細
タンパク質・核酸の鎖数16
化学式量合計374065.69
構造登録者
van Schooten, J.,Ward, A. (登録日: 2022-03-02, 公開日: 2022-08-10, 最終更新日: 2025-07-02)
主引用文献van Schooten, J.,Farokhi, E.,Schorcht, A.,van den Kerkhof, T.L.G.M.,Gao, H.,van der Woude, P.,Burger, J.A.,Meesters, T.G.R.,Bijl, T.,Ghalaiyini, R.,Turner, H.L.,Dorning, J.,van Schaik, B.D.C.,van Kampen, A.H.C.,Labranche, C.C.,Stanfield, R.L.,Sok, D.,Montefiori, D.C.,Burton, D.R.,Seaman, M.S.,Ozorowski, G.,Wilson, I.A.,Sanders, R.W.,Ward, A.B.,van Gils, M.J.
Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein.
Nat Commun, 13:4515-4515, 2022
Cited by
PubMed Abstract: A major goal of current HIV-1 vaccine design efforts is to induce broadly neutralizing antibodies (bNAbs). The VH1-2-derived bNAb IOMA directed to the CD4-binding site of the HIV-1 envelope glycoprotein is of interest because, unlike the better-known VH1-2-derived VRC01-class bNAbs, it does not require a rare short light chain complementarity-determining region 3 (CDRL3). Here, we describe three IOMA-class NAbs, ACS101-103, with up to 37% breadth, that share many characteristics with IOMA, including an average-length CDRL3. Cryo-electron microscopy revealed that ACS101 shares interactions with those observed with other VH1-2 and VH1-46-class bNAbs, but exhibits a unique binding mode to residues in loop D. Analysis of longitudinal sequences from the patient suggests that a transmitter/founder-virus lacking the N276 glycan might have initiated the development of these NAbs. Together these data strengthen the rationale for germline-targeting vaccination strategies to induce IOMA-class bNAbs and provide a wealth of sequence and structural information to support such strategies.
PubMed: 35922441
DOI: 10.1038/s41467-022-32208-0
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (3.95 Å)
構造検証レポート
Validation report summary of 7z3a
検証レポート(詳細版)ダウンロードをダウンロード

238895

件を2025-07-16に公開中

PDB statisticsPDBj update infoContact PDBjnumon